How to Switch From Compounded to Brand-Name GLP-1s Without Losing Progress

Whether it's Medicare coverage starting July 1, employer insurance adding GLP-1 benefits, or simply wanting the regulatory certainty of an FDA-approved product, many patients are transitioning from compounded to brand-name GLP-1s in 2026. Here's how to do it without losing progress.

The Critical Rule: No Gaps

Missing even one weekly dose of semaglutide can trigger rebound appetite and GI sensitivity when restarting. The goal is seamless overlap between your last compounded dose and your first brand-name dose.

Step-by-Step Transition Protocol

Step 1: Secure brand-name access first

Get your prescription, insurance authorization, and pharmacy fill confirmed BEFORE canceling your compounded provider. This process can take 1–3 weeks depending on insurance.

Step 2: Match your current dose

If you're on compounded semaglutide at 1mg/week, your brand-name equivalent is Wegovy 1mg. Your provider should match your dose — any provider who insists on restarting titration from 0.25mg without medical justification is wasting your time and money.

Step 3: Time the switch

Take your last compounded injection on your normal schedule. Take your first brand-name injection exactly one week later. Same day of the week, same time of day.

Step 4: Monitor for differences

Brand-name and compounded semaglutide contain the same active molecule, but excipients differ. Some patients notice slightly different GI effects during the first 1–2 weeks. These typically resolve.

Dose Equivalence Chart

Compounded Dose	Wegovy Equivalent	Notes
0.25mg/week	Wegovy 0.25mg	Initiation dose
0.5mg/week	Wegovy 0.5mg	Titration step
1.0mg/week	Wegovy 1.0mg	Titration step
1.7mg/week	Wegovy 1.7mg	Titration step
2.4mg/week	Wegovy 2.4mg	Current max approved dose
Custom higher doses	No direct equivalent yet	Wegovy 7.2mg pending approval

If Switching to Foundayo (Oral) Instead

Switching from injectable compounded semaglutide to oral Foundayo (orforglipron) is a medication change, not just a format change — it's a different molecule. Your provider will need to establish appropriate dosing from the beginning, as there's no direct dose equivalence between semaglutide and orforglipron.

If You're Not Ready to Switch

Ready for Brand-Name